Early-stage oncology startup Boundless Bio files for IPO
Boundless Bio has filed to go public as it approaches early safety and efficacy data for its first clinical attempt at a unique take on treating cancer.
The five-year-old San Diego startup revealed its plans Wednesday to trade on the Nasdaq as “BOLD.” The move comes as investor sentiment picks up with a flurry of follow-on offerings and renewed interest in crossover rounds.
Boundless, one of the many startups in ARCH Venture Partners’ sprawling portfolio, had previously raised about $250 million on the private side, including a $100 million Series C last May, shortly before it brought on ex-EQRx finance chief Jami Rubin to run finances.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
